Video

Physicians

Residents

Session: HEAD/NECK: Management of Potentially Virally-Mediated Malignancies of the Head and Neck

Oropharyngeal Cancer Therapeutic Developments in 2022: Open Your Mouth and Say…

Friday, March 11, 2022

1:15 PM – 2:05 PM US EST

Location: Las Olas IV, V, VI

Speaker(s)

David Raben, MD

VP, Global Product Oncology
Amgen
Greenwood Village , CO, United States

Disclosure: Amgen (Individual(s) Involved: Self): Currently I am a full time employee of Amgen in Global Oncology Development as well as holding an Adjoint professorship at University of Colorado Health, Employment (full or part time)

PDF Slides

Participants should be aware of the following financial/non-financial relationships:

David Raben, MD: Amgen (Individual(s) Involved: Self): Currently I am a full time employee of Amgen in Global Oncology Development as well as holding an Adjoint professorship at University of Colorado Health, Employment (full or part time)

Learning Objectives:

Describe the current approaches to oropharyngeal cancer management and review the emerging new therapies and studies that may transform care
Compile and interpret the studies that have evaluated dose or volume de-escalation in the management of oropharyngeal cancers
Illustrate and describe biomarkers that may contribute to adaptive changes in the management of oropharyngeal cancer